保守管理与腹腔镜胆囊切除术在预防成人无并发症有症状胆石病复发症状和并发症中的有效性(C-GALL试验):实用性、多中心随机对照试验
C-GALL试验在英國20个二级护理中心纳入434例无并发症有症状胆石病成人,随机分入保守管理组或腹腔镜胆囊切除术组。18个月内两组SF-36躯体疼痛曲线下面积无差异(均差0.0,95%CI -1.7至1.7;P=1.00),保守管理成本更低(均差-£1033,95%可信区间-£1413至-£632),QALYs无差异(均差-0.019,95%可信区间-0.06至0.02)。作者认为短期(≤18个月)腹腔镜手术并不比保守管理更有效,保守管理应被视为手术的替代选择。
要点
- 18个月内保守管理组与胆囊切除术组SF-36躯体疼痛曲线下面积无差异(均差0.0,95%CI -1.7至1.7;P=1.00)。
- 保守管理较胆囊切除术成本更低(均差-£1033,95%可信区间-£1413至-£632),QALYs无差异(均差-0.019,95%可信区间-0.06至0.02)。
- 作者认为短期(≤18个月)腹腔镜手术并不比保守管理更有效,保守管理应被视为手术的替代选择。
核心结论
- 在短期(≤18个月)内,对于无并发症有症状胆石病成人,腹腔镜手术并不比保守管理更有效,保守管理应被视为手术的替代选择。
- 从NHS角度看,保守管理对于无并发症有症状胆石病可能具有成本效果。
- 由于18个月后两组仍将持续产生成本、并发症和获益,未来研究应关注更长期随访以确定有效性和终生成本效果,并识别应常规接受手术的患者队列。
研究设计与样本
- 平行组、实用性随机、优效性试验,在英国20个二级护理中心开展。
- 纳入434例年龄>18岁、因无并发症有症状胆石病转诊至二级护理的成人,2016年8月至2019年11月期间评估资格,按1:1随机分配至保守管理组或腹腔镜胆囊切除术组。
- 保守管理组217例,腹腔镜胆囊切除术组217例。
主要发现
- 至18个月时,保守管理组54例(25%)参与者接受了手术,胆囊切除术组146例(67%)接受了手术。
- 保守管理组SF-36常模躯体疼痛评分均值为49.4(标准差11.7),胆囊切除术组为50.4(11.6)。
- 18个月内SF-36躯体疼痛曲线下面积无差异(均差0.0,95%置信区间-1.7至1.7;P=1.00)。
- 保守管理成本更低(均差-£1033(-$1334;-€1205),95%可信区间-£1413至-£632),QALYs无差异(均差-0.019,95%可信区间-0.06至0.02)。
关键数值与推荐
- 主要患者结局为18个月内SF-36躯体疼痛领域曲线下面积,评分范围0-100,评分越高表示生活质量越好。
- 其他结局包括NHS成本、质量调整生命年(QALYs)和增量成本效果比。
临床怎么用
- 作者认为在短期(≤18个月)内,腹腔镜手术并不比保守管理更有效,保守管理应被视为手术的替代选择。
- 作者指出从NHS角度看,保守管理对于无并发症有症状胆石病可能具有成本效果。
- 作者建议未来研究应关注更长期随访以确定有效性和终生成本效果,并识别应常规接受手术的患者队列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the clinical and cost effectiveness of conservative management compared with laparoscopic cholecystectomy for the prevention of symptoms and complications in adults with uncomplicated symptomatic gallstone disease. DESIGN: Parallel group, pragmatic randomised, superiority trial. SETTING: 20 secondary care centres in the UK. PARTICIPANTS: 434 adults (>18 years) with uncomplicated symptomatic gallstone disease referred to secondary care, assessed for eligibility between August 2016 and November 2019, and randomly assigned (1:1) to receive conservative management or laparoscopic cholecystectomy. INTERVENTIONS: Conservative management or surgical removal of the gallbladder. MAIN OUTCOME MEASURES: The primary patient outcome was quality of life, measured by area under the curve, over 18 months using the short form 36 (SF-36) bodily pain domain, with higher scores (range 0-100) indicating better quality of life. Other outcomes included costs to the NHS, quality adjusted life years (QALYs), and incremental cost effectiveness ratio. RESULTS: Of 2667 patients assessed for eligibility, 434 were randomised: 217 to the conservative management group and 217 to the laparoscopic cholecystectomy group. By 18 months, 54 (25%) participants in the conservative management arm and 146 (67%) in the cholecystectomy arm had received surgery. The mean SF-36 norm based bodily pain score was 49.4 (standard deviation 11.7) in the conservative management arm and 50.4 (11.6) in the cholecystectomy arm. The SF-36 bodily pain area under the curve up to 18 months did not differ (mean difference 0.0, 95% confidence interval -1.7 to 1.7; P=1.00). Conservative management was less costly (mean difference -£1033, (-$1334; -€1205), 95% credible interval -£1413 to -£632) and QALYs did not differ (mean difference -0.019, 95% credible interval -0.06 to 0.02). CONCLUSIONS: In the short term (≤18 months), laparoscopic surgery is no more effective than conservative management for adults with uncomplicated symptomatic gallstone disease, and as such conservative management should be considered as an alternative to surgery. From an NHS perspective, conservative management may be cost effective for uncomplicated symptomatic gallstone disease. As costs, complications, and benefits will continue to be incurred in both groups beyond 18 months, future research should focus on longer term follow-up to establish effectiveness and lifetime cost effectiveness and to identify the cohort of patients who should be routinely offered surgery. TRIAL REGISTRATION: ISRCTN registry ISRCTN55215960.
引用
- Ahmed I, Hudson J, Innes K, et al. Effectiveness of conservative management versus laparoscopic cholecystectomy in the prevention of recurrent symptoms and complications in adults with uncomplicated symptomatic gallstone disease (C-GALL trial): pragmatic, multicentre randomised controlled trial. BMJ. 2023. PMID: 38084426. doi:10.1136/bmj-2023-075383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。